Cargando…

Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing

(1) Background: Leclercia adecarboxylata (L. adecarboxylata) is a gram-negative bacillus of the Enterobacteriaceae family, which is uncommonly isolated from clinical specimens. L. adecarboxylata is considered as an aquatic opportunistic pathogen and most of the human infections are polymicrobial and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zayet, Souheil, Lang, Stephane, Garnier, Pauline, Pierron, Alix, Plantin, Julie, Toko, Lynda, Royer, Pierre-Yves, Villemain, Marc, Klopfenstein, Timothée, Gendrin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619052/
https://www.ncbi.nlm.nih.gov/pubmed/34832555
http://dx.doi.org/10.3390/pathogens10111399
_version_ 1784604896306135040
author Zayet, Souheil
Lang, Stephane
Garnier, Pauline
Pierron, Alix
Plantin, Julie
Toko, Lynda
Royer, Pierre-Yves
Villemain, Marc
Klopfenstein, Timothée
Gendrin, Vincent
author_facet Zayet, Souheil
Lang, Stephane
Garnier, Pauline
Pierron, Alix
Plantin, Julie
Toko, Lynda
Royer, Pierre-Yves
Villemain, Marc
Klopfenstein, Timothée
Gendrin, Vincent
author_sort Zayet, Souheil
collection PubMed
description (1) Background: Leclercia adecarboxylata (L. adecarboxylata) is a gram-negative bacillus of the Enterobacteriaceae family, which is uncommonly isolated from clinical specimens. L. adecarboxylata is considered as an aquatic opportunistic pathogen and most of the human infections are polymicrobial and usually occur in immunocompromised hosts. (2) Methods: In this retrospective study, we included all L. adecarboxylata strains since the introduction of MALDI-TOF MS in the Microbiology Department of Nord Franche-Comté Hospital, France (from 1 March 2015 to 31 July 2019). We studied demographic characteristics, comorbidities, characteristics of the current infection and outcome as well as antimicrobial susceptibility testing in all isolates. (3) Results: A total of 8 samples were identified (in 6 patients (4M/2F), with a recurrent L. adecarboxylata infection in 2 patients). The patients’ mean age was 66.2 years (range: 19–84). All patients were considered as immunocompetent, except a peritoneal dialysis patient with kidney transplantation. An exposition to an aquatic environment was identified in one patient. The most prevalent clinical feature was catheter-associated male urinary tract infection (in 3 cases) followed by ventilator-associated pneumonia (in 2 cases). One of 6 patients presented L. adecarboxylata bacteremia. L. adecarboxylata was part of a polymicrobial infection in 4 patients. The isolates showed a high susceptibility to all tested antibiotics, except one strain, which was resistant to fosfomycin. All patients with L. adecarboxylata infection were treated with antibiotics with a favorable outcome. (4) Conclusion: This study confirms the pathogenicity of L. adecarboxylata, even in immunocompetent patients, with a high susceptibility to antibiotics.
format Online
Article
Text
id pubmed-8619052
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86190522021-11-27 Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing Zayet, Souheil Lang, Stephane Garnier, Pauline Pierron, Alix Plantin, Julie Toko, Lynda Royer, Pierre-Yves Villemain, Marc Klopfenstein, Timothée Gendrin, Vincent Pathogens Article (1) Background: Leclercia adecarboxylata (L. adecarboxylata) is a gram-negative bacillus of the Enterobacteriaceae family, which is uncommonly isolated from clinical specimens. L. adecarboxylata is considered as an aquatic opportunistic pathogen and most of the human infections are polymicrobial and usually occur in immunocompromised hosts. (2) Methods: In this retrospective study, we included all L. adecarboxylata strains since the introduction of MALDI-TOF MS in the Microbiology Department of Nord Franche-Comté Hospital, France (from 1 March 2015 to 31 July 2019). We studied demographic characteristics, comorbidities, characteristics of the current infection and outcome as well as antimicrobial susceptibility testing in all isolates. (3) Results: A total of 8 samples were identified (in 6 patients (4M/2F), with a recurrent L. adecarboxylata infection in 2 patients). The patients’ mean age was 66.2 years (range: 19–84). All patients were considered as immunocompetent, except a peritoneal dialysis patient with kidney transplantation. An exposition to an aquatic environment was identified in one patient. The most prevalent clinical feature was catheter-associated male urinary tract infection (in 3 cases) followed by ventilator-associated pneumonia (in 2 cases). One of 6 patients presented L. adecarboxylata bacteremia. L. adecarboxylata was part of a polymicrobial infection in 4 patients. The isolates showed a high susceptibility to all tested antibiotics, except one strain, which was resistant to fosfomycin. All patients with L. adecarboxylata infection were treated with antibiotics with a favorable outcome. (4) Conclusion: This study confirms the pathogenicity of L. adecarboxylata, even in immunocompetent patients, with a high susceptibility to antibiotics. MDPI 2021-10-28 /pmc/articles/PMC8619052/ /pubmed/34832555 http://dx.doi.org/10.3390/pathogens10111399 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zayet, Souheil
Lang, Stephane
Garnier, Pauline
Pierron, Alix
Plantin, Julie
Toko, Lynda
Royer, Pierre-Yves
Villemain, Marc
Klopfenstein, Timothée
Gendrin, Vincent
Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_full Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_fullStr Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_full_unstemmed Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_short Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_sort leclercia adecarboxylata as emerging pathogen in human infections: clinical features and antimicrobial susceptibility testing
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619052/
https://www.ncbi.nlm.nih.gov/pubmed/34832555
http://dx.doi.org/10.3390/pathogens10111399
work_keys_str_mv AT zayetsouheil leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT langstephane leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT garnierpauline leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT pierronalix leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT plantinjulie leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT tokolynda leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT royerpierreyves leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT villemainmarc leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT klopfensteintimothee leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
AT gendrinvincent leclerciaadecarboxylataasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting